Epidemiological Context
- Human Papillomavirus (HPV) is the primary etiological driver of cervical, vulvar, vaginal, anal, penile, and oropharyngeal malignancies, alongside anogenital warts.
- Disease Burden in India: India accounts for nearly $20–25\%$ of global cervical cancer mortality, with over $1,25,000$ new cases and approximately $75,000–80,000$ deaths reported annually.
- Cervical cancer is the second most common cancer among Indian women after breast cancer.
- Public Health Goal: Aligning with the WHO Global Cervical Cancer Elimination Initiative (the "90-70-90 target" by 2030: $90\%$ of girls fully vaccinated with HPV vaccine by age 15, $70\%$ of women screened with high-performance tests by ages 35 and 45, and $90\%$ of women with pre-cancer/cancer treated).
Vaccine Formulations Available In India
| Parameter | Cervavac (SII Quadrivalent) | Gardasil (Quadrivalent) | Gardasil-9 (9-valent) |
|---|---|---|---|
| Manufacturer | Serum Institute of India (SII) | Merck Sharp & Dohme (MSD) | Merck Sharp & Dohme (MSD) |
| Antigenic Strains | HPV 6, 11, 16, 18 | HPV 6, 11, 16, 18 | HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 |
| Production Platform | Virus-Like Particles (VLPs) in Hansenula polymorpha yeast | VLPs in Saccharomyces cerevisiae yeast | VLPs in Saccharomyces cerevisiae yeast |
| Adjuvant | Aluminum hydroxyphosphate sulfate | Amorphous aluminum hydroxyphosphate sulfate (AAHS) | Amorphous aluminum hydroxyphosphate sulfate (AAHS) |
| Cervical Cancer Protection | $\sim 70–80\%$ | $\sim 70–80\%$ | $\sim 90–98\%$ |
| Public Health Advantage | Indigenous development, highly affordable (approx. ₹200–400/dose in public supply) | High commercial cost | Highest broad-spectrum protection, but highest retail price |
Landmark Evidence (WHO 2022)
The WHO Strategic Advisory Group of Experts (SAGE) updated HPV guidelines in 2022, concluding that an off-label single-dose schedule provides comparable efficacy and durability to a 2-dose regimen in girls aged 9 to 14 years.
Key Clinical Trials
- The KEN SHE Trial (Kenya Single-Dose HPV Vaccine Efficacy Study, NEJM 2022):
- Randomized controlled trial in young Kenyan women aged 15–20 years.
- Findings: A single dose of either bivalent or nonavalent HPV vaccine demonstrated $97.5\%$ vaccine efficacy against persistent oncogenic HPV 16/18 infection over 18 to 36 months, statistically indistinguishable from multi-dose regimens.
- The DoRIS Trial (Tanzania):
- Assessed immune non-inferiority of 1 dose vs 2 vs 3 doses.
- Showed that antibody titers after 1 dose, although lower than after 2 or 3 doses, remained stable, high-affinity, and plateaued above natural infection titers with sustained avidity over 3+ years.
- IARC / NCI Long-Term Indian Cohort (Sankaranarayanan et al., Lancet Oncology):
- Observational follow-up of unmarried Indian girls receiving 1, 2, or 3 doses of quadrivalent vaccine.
- Demonstrated durable protection against persistent HPV 16/18 infection for over 10 to 12 years following a single dose.
National Immunization Rollout & IAP ACVIP Guidelines
flowchart TD
A["Target Demographics for HPV Immunization"] --> B{"Setting / Program"}
B -->|"India Public Health / NTAGI Rollout"| C["<b>Target: Girls aged 9–14 years</b><br>• Focus on school-based & U-WIN tracking<br>• Primary vaccine: Quadrivalent (Cervavac / qHPV)<br>• Single-dose schedule supported for public scale-up"]
B -->|"Private Practice / IAP ACVIP 2024–2025"| D["<b>Gender-Neutral Approach (Boys & Girls)</b><br>• Age 9–14 years: 2 doses (0, 6 months)<br>• Age ≥ 15 years: 3 doses (0, 1–2, 6 months)<br>• 9-valent (Gardasil-9) preferred where affordable"]
C --> E["Immunocompromised / HIV: Mandatory 3 doses (0, 2, 6 mo)"]
D --> E
Dosing Guidelines Summary
| Target Group | WHO SAGE (2022) | National Campaign (UIP/NTAGI) | IAP ACVIP (Private Sector) |
|---|---|---|---|
| Girls aged 9–14 years | 1-dose or 2-dose schedule | Single-dose / 2-dose schedule (focus on 9–14y girls) | 2-dose schedule (0 and 6 months; min interval 5 months) |
| Females aged 15–20 years | 1-dose or 2-dose schedule | Routine rollout focused on 9–14y | 3-dose schedule (0, 1–2, 6 months) |
| Females aged $>21$ years | 2 doses with 6-month interval | Not included in routine public supply | 3-dose schedule up to 26 years (shared decision up to 45y) |
| Immunocompromised (including HIV) | Minimum 2 doses, ideally 3 doses | 3 doses (0, 2, 6 months) | 3 doses (0, 2, 6 months) |
Administration, Storage, And Safety
- Dose & Route: $0.5\text{ mL}$ intramuscularly into the deltoid region.
- Cold Chain Maintenance: Strict storage at $+2^\circ\text{C}\text{ to }+8^\circ\text{C}$. Do not freeze. Freezing destabilizes the aluminum adjuvant lattice, causing irreversible aggregation and complete loss of immunogenicity.
- Vasovagal Syncope Precautions: All vaccinees must be observed seated or recumbent for 15 minutes post-injection to mitigate injuries secondary to psychogenic syncopal episodes common in adolescents.
- Safety Profile: No increased incidence of complex regional pain syndrome (CRPS), postural orthostatic tachycardia syndrome (POTS), or autoimmune neurological disorders in large global post-licensure safety surveillance databases.